Free Trial

Vivos Therapeutics Q3 2023 Earnings Report

Vivos Therapeutics logo
$5.61 -0.13 (-2.26%)
As of 04:00 PM Eastern

Vivos Therapeutics EPS Results

Actual EPS
-$1.75
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Vivos Therapeutics Revenue Results

Actual Revenue
$3.30 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vivos Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Vivos Therapeutics Earnings Headlines

Vivos to sell 709,220 shares at $4.935 in registered direct offering
Do this Before Elon’s Reveal on January 29th
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
Vivos Therapeutics announces funding boost
See More Vivos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vivos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vivos Therapeutics and other key companies, straight to your email.

About Vivos Therapeutics

Vivos Therapeutics (NASDAQ:VVOS), a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

View Vivos Therapeutics Profile

More Earnings Resources from MarketBeat